NCI grants Solixia $161K for ovarian cancer research
Radiopharmaceutical company Solixia has been awarded a $161,000 Phase I small business innovation research grant from the National Cancer Institute (NCI) for its project that will develop and test a pharmaceutical agent for the treatment for ovarian cancer.
According to the Philadelphia-based company, its radioimmunotherapy uses molecules to deliver radioactivity to ovarian cancer cells, as the disease has not proven to respond well to conventional chemotherapy.
The grant will support laboratory testing of Solixia’s compound and the research team has planned to achieve first-in-man studies in early 2012. The team also hopes to utilize these initial data to expand its technology to other imaging and treatment settings.
According to the Philadelphia-based company, its radioimmunotherapy uses molecules to deliver radioactivity to ovarian cancer cells, as the disease has not proven to respond well to conventional chemotherapy.
The grant will support laboratory testing of Solixia’s compound and the research team has planned to achieve first-in-man studies in early 2012. The team also hopes to utilize these initial data to expand its technology to other imaging and treatment settings.